SG11201906169QA - Composition for the prevention or the treatment of visual impairments comprising ursodeoxycholic acid - Google Patents

Composition for the prevention or the treatment of visual impairments comprising ursodeoxycholic acid

Info

Publication number
SG11201906169QA
SG11201906169QA SG11201906169QA SG11201906169QA SG11201906169QA SG 11201906169Q A SG11201906169Q A SG 11201906169QA SG 11201906169Q A SG11201906169Q A SG 11201906169QA SG 11201906169Q A SG11201906169Q A SG 11201906169QA SG 11201906169Q A SG11201906169Q A SG 11201906169QA
Authority
SG
Singapore
Prior art keywords
prevention
treatment
ursodeoxycholic acid
composition
visual impairments
Prior art date
Application number
SG11201906169QA
Inventor
Yeong Ho Song
Hwi Jin Ko
Original Assignee
Yoos Biopharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yoos Biopharm Inc filed Critical Yoos Biopharm Inc
Priority claimed from PCT/KR2018/001770 external-priority patent/WO2018147685A1/en
Publication of SG11201906169QA publication Critical patent/SG11201906169QA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/718—Starch or degraded starch, e.g. amylose, amylopectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Physiology (AREA)
  • Endocrinology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Nutrition Science (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

This disclosure relates to a composition for the prevention or the treatment of visual impairments comprising ursodeoxycholic acid (UDCA). More particularly, this disclosure relates to an excellent pharmaceutical composition for the prevention or the treatment of visual impairments such as macular degeneration, glaucoma and diabetic retinopathy which can be 5 formulated for an oral administration, an intravitreal injection, or an eye drop administration by aqueous solubilized ursodeoxycholic acid. FIG. 7C
SG11201906169QA 2017-02-09 2018-02-09 Composition for the prevention or the treatment of visual impairments comprising ursodeoxycholic acid SG11201906169QA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR20170018220 2017-02-09
KR1020180015944A KR102252450B1 (en) 2017-02-09 2018-02-08 Composition for prevention or treatment of visual disorders comprising ursodeoxycholic acid
PCT/KR2018/001770 WO2018147685A1 (en) 2017-02-09 2018-02-09 Composition containing ursodeoxycholic acid for prevention or treatment of visual impairment

Publications (1)

Publication Number Publication Date
SG11201906169QA true SG11201906169QA (en) 2019-08-27

Family

ID=63443030

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201906169QA SG11201906169QA (en) 2017-02-09 2018-02-09 Composition for the prevention or the treatment of visual impairments comprising ursodeoxycholic acid

Country Status (12)

Country Link
US (2) US20190255074A1 (en)
EP (1) EP3581185A4 (en)
JP (2) JP6901739B2 (en)
KR (3) KR102252450B1 (en)
CN (1) CN110177556A (en)
AU (3) AU2018218696B2 (en)
BR (1) BR112019009202A2 (en)
CA (1) CA3039500C (en)
GB (1) GB2571644A (en)
MX (1) MX2019008963A (en)
RU (2) RU2746592C1 (en)
SG (1) SG11201906169QA (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9840553B2 (en) 2014-06-28 2017-12-12 Kodiak Sciences Inc. Dual PDGF/VEGF antagonists
AU2016381964B2 (en) 2015-12-30 2024-02-15 Kodiak Sciences Inc. Antibodies and conjugates thereof
KR102252450B1 (en) * 2017-02-09 2021-05-14 주식회사 아미코젠파마 Composition for prevention or treatment of visual disorders comprising ursodeoxycholic acid
BR112021011653A2 (en) * 2018-12-18 2021-09-08 Santen Pharmaceutical Co., Ltd. AGENT CONTAINING URSODEOXYCHOLIC ACID FOR THE TREATMENT OR PREVENTION OF PRESBYOPIA
WO2021072265A1 (en) 2019-10-10 2021-04-15 Kodiak Sciences Inc. Methods of treating an eye disorder
KR102624174B1 (en) 2020-09-18 2024-01-23 주식회사 아미코젠파마 Pharmaceutical composition comprising aqueous solubilized bile acid for the prevention or treatment of sepsis, acute lung injury disease, or acute respiratory distress syndrome
WO2022173043A1 (en) * 2021-02-15 2022-08-18 参天製薬株式会社 Water-based pharmaceutical composition containing ursodeoxycholic acid or salt thereof
CN113151206A (en) * 2021-04-21 2021-07-23 重庆第二师范学院 3 alpha-hydroxysteroid dehydrogenase, coding gene and application thereof

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7772220B2 (en) * 2004-10-15 2010-08-10 Seo Hong Yoo Methods and compositions for reducing toxicity of a pharmaceutical compound
RU2224523C2 (en) * 1998-07-24 2004-02-27 Сео Хонг Ю Bile acid-containing aqueous solution and method for its preparing
US20050158408A1 (en) * 1998-07-24 2005-07-21 Yoo Seo H. Dried forms of aqueous solubilized bile acid dosage formulation: preparation and uses thereof
BR0108080A (en) * 2000-02-04 2006-02-07 Seo Hong Yoo Preparation of aqueous clear bile acid solution dosage forms
ATE458489T1 (en) * 2004-08-30 2010-03-15 Seo Hong Yoo NERVE PROTECTIVE EFFECT OF DISSOLVED UDCA IN A FOCAL ISCHEMIC MODEL
WO2006050165A2 (en) * 2004-11-01 2006-05-11 Seo Hong Yoo Methods and compositions for reducing neurodegeneration in amyotrophic lateral sclerosis
ES2358089T3 (en) * 2004-11-01 2011-05-05 Seo Hong Yoo METHODS AND COMPOSITIONS TO REDUCE NEURODEGENERATION IN AMIOTROPHIC SIDE STERHERISIS.
WO2006057637A1 (en) * 2004-11-24 2006-06-01 Seo Hong Yoo Dried forms of aqueous solubilized bile acid dosage formulation: preparation and uses thereof
KR20080012258A (en) * 2005-02-10 2008-02-11 리전츠 오브 더 유니버스티 오브 미네소타 Methods for treating visual disorders
KR20080061327A (en) * 2006-12-27 2008-07-02 성균관대학교산학협력단 Composition comprising soluble udca for preventing and treating colon cancer
JP5594695B2 (en) * 2009-04-23 2014-09-24 国立大学法人 鹿児島大学 Angiogenesis inhibitor
US9724357B2 (en) * 2011-08-15 2017-08-08 Massachusetts Eye & Ear Infirmary Methods for preserving photoreceptor cell viability following retinal detachment
TW201609145A (en) * 2013-12-25 2016-03-16 參天製藥股份有限公司 Injectable agent and depot formation method
MX2016009331A (en) 2014-01-23 2016-10-26 Akebia Therapeutics Inc Compositions and methods for treating ocular diseases.
CN104083381A (en) * 2014-07-29 2014-10-08 上海中医药大学 Medical application of ursodesoxycholic acid
KR102252450B1 (en) * 2017-02-09 2021-05-14 주식회사 아미코젠파마 Composition for prevention or treatment of visual disorders comprising ursodeoxycholic acid

Also Published As

Publication number Publication date
AU2020204384B2 (en) 2021-10-21
US20190255074A1 (en) 2019-08-22
MX2019008963A (en) 2019-09-10
AU2020204384A1 (en) 2020-07-23
KR20180092886A (en) 2018-08-20
EP3581185A4 (en) 2020-10-28
US20210252022A1 (en) 2021-08-19
KR102252450B1 (en) 2021-05-14
RU2746592C1 (en) 2021-04-16
JP2021143192A (en) 2021-09-24
AU2021204660A1 (en) 2021-07-29
BR112019009202A2 (en) 2020-03-03
AU2018218696B2 (en) 2020-04-09
JP6901739B2 (en) 2021-07-14
GB2571644A (en) 2019-09-04
KR20190135955A (en) 2019-12-09
CA3039500C (en) 2021-07-13
KR102382077B1 (en) 2022-04-04
CA3039500A1 (en) 2018-06-16
JP2019532082A (en) 2019-11-07
GB201904993D0 (en) 2019-05-22
AU2018218696A1 (en) 2019-06-13
CN110177556A (en) 2019-08-27
KR20220000881A (en) 2022-01-04
EP3581185A1 (en) 2019-12-18
RU2723988C1 (en) 2020-06-18

Similar Documents

Publication Publication Date Title
SG11201906169QA (en) Composition for the prevention or the treatment of visual impairments comprising ursodeoxycholic acid
WO2016134223A3 (en) Fluorinated tetrahydronaphthyridinyl nonanoic acid derivatives and uses thereof
PH12019550088A1 (en) Preparation of solid cyclodextrin complexes for ophthalmic active pharmaceutical ingredient delivery
MX2018014868A (en) Compositions and methods of using nintedanib for improving glaucoma surgery success.
MX350951B (en) COMPOSITIONS and METHODS FOR TREATING RETINAL DISEASES.
MX2019001877A (en) Ophthalmic pharmaceutical compositions and uses relating thereto.
MY171920A (en) Prevention and treatment of ocular conditions
MX2017002374A (en) Compositions and methods to treat vision disorders.
WO2007046083A3 (en) Compositions for treatment of eye diseases
PH12017502155A1 (en) Formation of cyclosporin a/cyclodextrin nanoparticles
MX2023003230A (en) Pro.
WO2016100949A3 (en) Method and compositions for dissolving or solubilizing therapeutic agents
BR112022011102A2 (en) TREATMENTS OF DIABETIC MACULAR EDEMA AND DEFICIENT VISUAL ACUITY
EA202191684A1 (en) DRUG CONTAINING URSODEOXYCHOLIC ACID FOR TREATMENT OR PREVENTION OF PRESBIOPIA
MX2016016090A (en) Ophthalmic composition for the treatment of ocular infection.
WO2013189606A3 (en) Interval therapy for the treatment of loss of eyesight in humans with glaucoma and other degenerative eye diseases
EP4245295A3 (en) Compounds and pharmaceutical compositions for use in treating retina-associated disease using ccr3-inhibitors
WO2015048188A8 (en) Modified fibroblast growth factors for the treatment of ocular disorders
MX2021006070A (en) Ocular formulations for drug-delivery and protection of the anterior segment of the eye.
MX2017004760A (en) Heat-sterilized formulation comprising chitosan and process of preparation thereof.
AU2018240462A1 (en) Drugs and compositions for the treatment of ocular disorders
WO2016126058A3 (en) Solid dispersion containing dutasteride, and composition containing same
WO2008152507A3 (en) Compositions and methods for treating ophthalmic disorders
MX2021012960A (en) Compositions and methods for use of cannabinoids for neuroprotection.
MX2017016858A (en) Immunogenic compositions.